We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OPKO Health (OPK) Q1 Earnings Match Estimates, Revenues Top
Read MoreHide Full Article
OPKO Health, Inc. (OPK - Free Report) reported first-quarter 2021 adjusted earnings per share (EPS) of 5 cents per share, which met the Zacks Consensus Estimate. Notably, the company had reported a loss of 9 cents in the prior-year quarter.
Revenue Details
First-quarter revenues of this Zacks Rank #3 (Hold) company were $545.2 million, which surpassed the Zacks Consensus Estimate by 8.4%. The top line also improved 157.8% on a year-over-year basis.
Segmental Revenues in Q1
Revenues from Services amounted to $507 million in the reported quarter, up 196.8% year over year driven by COVID-19 testing volume. However, decline in revenues in the company’s bases testing business, which represents the negative impact of the COVID-19 pandemic, partially offset the upside.
Revenues from Products rose 9% to $33.9 million owing to higher sales in OPKO Chile and FinTech. However, lower sales in RAYALDEE partially offset the upside.
OPKO Health, Inc. Price, Consensus and EPS Surprise
Revenues from Transfer of intellectual property totaled $4.3 million, down 55.2% year over year, due to a decline in the amortization of payments received from Pfizer associated with somatrogon.
Per management, total RAYALDEE prescriptions declined 32.8% year over year in the first quarter. During the quarter under review, the company witnessed a decline in sales of RAYALDEE due to the impact of the pandemic.
Margin Analysis
Gross profit in the reported quarter was $181.7 million, up 155.2% from the prior-year quarter. Gross margin was 33.3% of net revenues, down 40 basis points (bps) year over year.
Selling, general and administrative expenses totaled $112.3 million, up 47.6% year over year. Research and development expenses amounted to $19.3 million, down 11.5% year over year.
Operating income in the first quarter was $38.5 million, against the year-ago quarter’s loss of $40.7 million.
Financial Update
The company exited the first quarter with cash, cash equivalents and marketable securities of $89.5 million, compared with $72.2 million on a sequential basis.
Guidance
In the quarter under review, OPKO Health refrained from issuing any guidance.
Summing Up
OPKO Health exited the first quarter on a mixed note. Further, its utilization of the 4Kscore remains strong. Also, the company witnessed strength across its Services and Products segments in the quarter under review.
Regulatory approvals and presentations of clinical data from studies during the first quarter are highlights.
Furthermore, BioReference Laboratories COVID-19 testing volume witnessed a significant increase in the first quarter.
Meanwhile, contraction in gross margin remains a woe. Moreover, decline in sales of RAYALDEE is a concern. Further, OPKO Health continues to face cut-throat competition in the MedTech space.
DENTSPLY SIRONA is set to release results on May 6. The Zacks Consensus Estimate for DENTSPLY SIRONA’s first-quarter 2021 adjusted EPS is pegged at 55 cents, suggesting growth of 27.9% from the year-ago quarter. The consensus mark for first-quarter revenues stands at $929.3 million, indicating year-over-year increase of 6.3%.
The Zacks Consensus Estimate for Cooper Companies’ fiscal second-quarter 2021 revenues is pegged at $685.2 million, suggesting year-over-year improvement of 30.5%. The same for EPS stands at $3.04, indicating growth of 101.3% from the year-ago reported figure.
The Zacks Consensus Estimate for Owens & Minor’s first-quarter 2021 EPS is currently pegged at 97 cents, indicating significant growth from the year-ago reported figure. The same for revenues stands at $2.29 billion, indicating an improvement of 7.9% from the year-ago reported figure.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
Image: Bigstock
OPKO Health (OPK) Q1 Earnings Match Estimates, Revenues Top
OPKO Health, Inc. (OPK - Free Report) reported first-quarter 2021 adjusted earnings per share (EPS) of 5 cents per share, which met the Zacks Consensus Estimate. Notably, the company had reported a loss of 9 cents in the prior-year quarter.
Revenue Details
First-quarter revenues of this Zacks Rank #3 (Hold) company were $545.2 million, which surpassed the Zacks Consensus Estimate by 8.4%. The top line also improved 157.8% on a year-over-year basis.
Segmental Revenues in Q1
Revenues from Services amounted to $507 million in the reported quarter, up 196.8% year over year driven by COVID-19 testing volume. However, decline in revenues in the company’s bases testing business, which represents the negative impact of the COVID-19 pandemic, partially offset the upside.
Revenues from Products rose 9% to $33.9 million owing to higher sales in OPKO Chile and FinTech. However, lower sales in RAYALDEE partially offset the upside.
OPKO Health, Inc. Price, Consensus and EPS Surprise
OPKO Health, Inc. price-consensus-eps-surprise-chart | OPKO Health, Inc. Quote
Revenues from Transfer of intellectual property totaled $4.3 million, down 55.2% year over year, due to a decline in the amortization of payments received from Pfizer associated with somatrogon.
Per management, total RAYALDEE prescriptions declined 32.8% year over year in the first quarter. During the quarter under review, the company witnessed a decline in sales of RAYALDEE due to the impact of the pandemic.
Margin Analysis
Gross profit in the reported quarter was $181.7 million, up 155.2% from the prior-year quarter. Gross margin was 33.3% of net revenues, down 40 basis points (bps) year over year.
Selling, general and administrative expenses totaled $112.3 million, up 47.6% year over year. Research and development expenses amounted to $19.3 million, down 11.5% year over year.
Operating income in the first quarter was $38.5 million, against the year-ago quarter’s loss of $40.7 million.
Financial Update
The company exited the first quarter with cash, cash equivalents and marketable securities of $89.5 million, compared with $72.2 million on a sequential basis.
Guidance
In the quarter under review, OPKO Health refrained from issuing any guidance.
Summing Up
OPKO Health exited the first quarter on a mixed note. Further, its utilization of the 4Kscore remains strong. Also, the company witnessed strength across its Services and Products segments in the quarter under review.
Regulatory approvals and presentations of clinical data from studies during the first quarter are highlights.
Furthermore, BioReference Laboratories COVID-19 testing volume witnessed a significant increase in the first quarter.
Meanwhile, contraction in gross margin remains a woe. Moreover, decline in sales of RAYALDEE is a concern. Further, OPKO Health continues to face cut-throat competition in the MedTech space.
Key Picks
Some better-ranked stocks, which are expected to report earnings soon, are DENTSPLY SIRONA Inc. (XRAY - Free Report) , The Cooper Companies, Inc. (COO - Free Report) and Owens & Minor, Inc. (OMI - Free Report) , each carrying a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
DENTSPLY SIRONA is set to release results on May 6. The Zacks Consensus Estimate for DENTSPLY SIRONA’s first-quarter 2021 adjusted EPS is pegged at 55 cents, suggesting growth of 27.9% from the year-ago quarter. The consensus mark for first-quarter revenues stands at $929.3 million, indicating year-over-year increase of 6.3%.
The Zacks Consensus Estimate for Cooper Companies’ fiscal second-quarter 2021 revenues is pegged at $685.2 million, suggesting year-over-year improvement of 30.5%. The same for EPS stands at $3.04, indicating growth of 101.3% from the year-ago reported figure.
The Zacks Consensus Estimate for Owens & Minor’s first-quarter 2021 EPS is currently pegged at 97 cents, indicating significant growth from the year-ago reported figure. The same for revenues stands at $2.29 billion, indicating an improvement of 7.9% from the year-ago reported figure.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>